Study Shows Downward Trend in Sovaldi UtilizationStudy Shows Downward Trend in Sovaldi Utilization

Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Infectious Diseases News Source Type: news